Comparison of hepatic steatosis index as noninvasive diagnostic tool and liver ultrasound for non-alcoholic steatosis in the adult population Hepatic steatosis index for non-alcoholic steatosis diagnosis
Gastroenterology and Hepatology from Bed to Bench,
Vol. 15 No. 4 (2022),
3 Mehr 2022
Aim: This study aimed to evaluate hepatic steatosis index (HSI) as a non-invasive tool in diagnosing and predicting NASH and to compare it with abdominal ultrasound as the gold standard tool.
Background: Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD) with inflammation which can progress to liver cirrhosis. Rapid and valid screening can remarkably prevent the progression of this disease.
Methods: A total of 464 people were included in the present study based on inclusion criteria. Patients were evaluated for (BMI), AST, ALT, and ALP indices. The liver echogenicity of patients was evaluated by abdominal ultrasound technique, and patients were classified.
Results: The results showed that out of 464 people included in the study, 32.33% represented fatty liver. It was found that 79.1% of patients were female. There was no significant difference between the two groups in terms of age. Furthermore, it was found that ALT, AST, and ALP levels were significantly increased in the two groups of patients compared to the control group. It was determined that out of 150 patients, 75.3% were grade I and 24.7% were grade II NASH cases; no grade III cases were observed. The mean HSI for the NASH- group was 35.51±5.72 and for the NASH+ group was 42.84±5.70, a significant difference. The receiver operating characteristic (ROC) curve also showed that the area under the curve (AUC) of HSI was 0.833 (95% CI, 0.796-0.870) for detecting NASH patients. At the cutoff point of > 37.0, the sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) were 84.0% (95% CI, 77.2 -89.0), 70.1% (95% CI, 64.8 -74.9), 90.2%, and 57.3%, respectively. Pearson correlation showed a direct and significant correlation between ultrasound data and HSI values.
Conclusion: Overall, the present study results showed that HSI as a non-invasive and non-imaging tool can diagnose NASH.
- Non-alcoholic Fatty Liver Disease
- Fatty Liver
How to Cite
Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 2019;71:793-801.
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11-20.
Piazzolla VA, Mangia A. Noninvasive Diagnosis of NAFLD and NASH. Cells 2020;9:1005.
Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan W-K, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020;5:362-73.
Ægidius HM, Veidal SS, Feigh M, Hallenborg P, Puglia M, Pers TH, et al. Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis. Sci Rep 2020;10:1-12.
Kakehashi A, Stefanov VE, Ishii N, Okuno T, Fujii H, Kawai K, et al. Proteome characteristics of non-alcoholic steatohepatitis liver tissue and associated hepatocellular carcinomas. Int J Mol Sci 2017;18:434.
Manne V, Handa P, Kowdley KV. Pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Clin Liver Dis 2018;22:23-37.
Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43:S99-S112.
Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol 2013;28:64-70.
Ballestri S, Lonardo A, Romagnoli D, Carulli L, Losi L, Day CP, et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int 2012;32:1242-52.
Ballestri S, Romagnoli D, Nascimbeni F, Francica G, Lonardo A. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev Gastroenterol Hepatol 2015;9:603-27.
Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol 2007;102:2716-7.
Lee J-H, Kim D, Kim HJ, Lee C-H, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010;42:503-8.
Sviklāne L, Olmane E, Dzērve Z, Kupčs K, Pīrāgs V, Sokolovska J. Fatty liver index and hepatic steatosis index for prediction of non‐alcoholic fatty liver disease in type 1 diabetes. J Gastroenterol Hepatol 2018;33:270-6.
Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:1-7.
Parthasarathy G, Revelo X, Malhi H. Pathogenesis of nonalcoholic steatohepatitis: an overview. Hepatol Commun 2020;4:478-92.
Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. Jama 2020;323:1175-83.
Bugianesi E. Late complications of NASH: a challenge for hepatologists. J Hepatol 2005;42:784-5.
Kogachi S, Noureddin M. Noninvasive evaluation for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Ther 2021.
Tincopa MA. Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis. Endocrinol Diabetes Metabol 2020;3:00177.
Murayama K, Okada M, Tanaka K, Inadomi C, Yoshioka W, Kubotsu Y, et al. Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. Diagnostics 2021;11:132.
Vesa CM, Behl T, Nemeth S, Bratu OG, Diaconu CC, Moleriu RD, et al. Prediction of NAFLD occurrence in prediabetes patients. Exp Ther Med 2020;20:1.
- Abstract Viewed: 45 times
- PDF Downloaded: 34 times